Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be more than 750,000 patients annually worldwide
New pacemakers offer 40% more battery life,1 extend Medtronic legacy of pacing leadership
DUBLIN, Jan. 5, 2024 /PRNewswire/ Medtronic plc , a global leader in healthcare technology, today.